SEC Form 4 · accession 0001225208-26-006103
Edwards Lifesciences Corp · EW
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Bernard J Zovighian
Officer — CEO · Director
Period of report
Jun 17, 2026
Accepted (ET)
Jun 17, 2026 · 8:19 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001099800
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 17, 2026 | S | 523 | $87.92 | D | 11,517 | I | By Trust |
| Common Stock | holding | — | — | — | 99,165 | D | ||
| Common Stock | holding | — | — | — | 3,734 | I | 401(k) |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 12, 2025.
Remarks
This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.